• What best describes your title?*
  • If PharmD, DOB
     - -
    2 digit month, 2 digit day, 4 digit year
  • 1. According to the 2025 GOLD guidelines, which of the following remains the cornerstone of initial pharmacologic therapy for patients with moderate-to-severe COPD?*
  • 2. The 2025 GOLD guidelines emphasize which key change compared to prior versions in managing exacerbation-prone COPD patients?*
  • 3. Which statement best reflects recent clinical trial data regarding nebulized LAMA therapy for COPD?*
  • 4. In recent randomized trials evaluating nebulized revefenacin for COPD, which outcome was most consistently improved?*
  • 5. When selecting long-acting nebulized therapy for COPD maintenance, which clinical factor should most influence treatment choice according to GOLD recommendations?*
  • 6. Which strategy best supports adherence and optimized outcomes with long-acting nebulized COPD maintenance therapy?*
  • How many patients do you currently see each month regarding chronic obstructive pulmonary disease (COPD)?
  • Learning Objectives
    Rows
  • Please provide us with feedback regarding your experience at the activity:
    Rows
  • Do you feel this activity was fair, balanced, and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

  • Attestation:

    AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

    Participants should claim only the credit commensurate with the extent of their participation in the activity.

  • Date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: